Showing results (51-60 of 82) with videos related to
Sort By:
Pageof 9
Histochemistry and Cell Biology|September 28, 1998
Endocytosis by the corneal endothelium. I. Regulation of binding and transport of hemeproteins and peroxidase-conjugated lectins across the tissueS R Gordon, D Czerwinski-Mowers, J Marchand, et al.Investigational New Drugs|June 9, 1999
Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancerK Rajagopalan, D Peereboom, G T Budd, et al.Applied Optics|October 17, 2014
Advanced mesospheric temperature mapper for high-latitude airglow studiesP-D Pautet, M J Taylor, W R Pendleton, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 1, 1994
Amifostine: potential for clinically useful cytoprotectionG T Budd, V Lorenzi, R Ganapathi, et al.Journal of Cancer Research and Clinical Oncology|October 16, 2001
GM-CSF safety and effects in the management of advanced/refractory multiple myeloma patients: a phase I trialM A Hussein, K Sandstrom, P Elson, et al.Experientia|August 15, 1975
Seasonal variations in mitosis in the frog: a field studyH Rothstein, R G Van Buskirk, S R Gordon, et al.Cellular and Molecular Biology (Noisy-Le-Grand, France)|March 1, 1996
Regional differences in the distribution of catalase in the epithelium of the ocular lensJ R Reddan, C A Steiger, D C Dziedzic, et al.Journal of Cancer Research and Clinical Oncology|May 18, 2001
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinomaT Olencki, D Peereboom, L Wood, et al.Journal of Cancer Research and Clinical Oncology|January 1, 1994
A phase I trial of intrapleural recombinant human interferon alpha (rHuIFN alpha 2b) in patients with malignant pleural effusionsA Bhatia, T W Rice, D McLain, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 23, 2000
Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: clinical and biologic effectsT Olencki, J Finke, R Tubbs, et al.Pageof 9